Aevi Genomic Medicine Inc (GNMX) Expected to Post Earnings of -$0.16 Per Share

Wall Street brokerages predict that Aevi Genomic Medicine Inc (NASDAQ:GNMX) will report earnings per share (EPS) of ($0.16) for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have provided estimates for Aevi Genomic Medicine’s earnings, with the lowest EPS estimate coming in at ($0.17) and the highest estimate coming in at ($0.15). Aevi Genomic Medicine posted earnings of ($0.23) per share during the same quarter last year, which would suggest a positive year-over-year growth rate of 30.4%. The company is scheduled to report its next earnings report on Thursday, November 1st.

On average, analysts expect that Aevi Genomic Medicine will report full year earnings of ($0.60) per share for the current fiscal year, with EPS estimates ranging from ($0.61) to ($0.59). For the next financial year, analysts anticipate that the business will post earnings of ($0.92) per share, with EPS estimates ranging from ($1.27) to ($0.57). Zacks’ earnings per share calculations are a mean average based on a survey of research analysts that follow Aevi Genomic Medicine.

Aevi Genomic Medicine (NASDAQ:GNMX) last posted its earnings results on Thursday, August 2nd. The biotechnology company reported ($0.14) EPS for the quarter, topping analysts’ consensus estimates of ($0.15) by $0.01.

Separately, ValuEngine raised shares of Aevi Genomic Medicine from a “strong sell” rating to a “sell” rating in a research report on Wednesday, May 2nd.

NASDAQ:GNMX traded down $0.03 during trading hours on Tuesday, reaching $0.98. The company had a trading volume of 17,467 shares, compared to its average volume of 106,832. Aevi Genomic Medicine has a 52 week low of $0.83 and a 52 week high of $2.65.

Institutional investors have recently modified their holdings of the company. Renaissance Technologies LLC boosted its stake in shares of Aevi Genomic Medicine by 515.8% during the 4th quarter. Renaissance Technologies LLC now owns 93,600 shares of the biotechnology company’s stock worth $112,000 after acquiring an additional 78,400 shares during the last quarter. JPMorgan Chase & Co. boosted its stake in shares of Aevi Genomic Medicine by 4,715.1% during the 1st quarter. JPMorgan Chase & Co. now owns 101,118 shares of the biotechnology company’s stock worth $203,000 after acquiring an additional 99,018 shares during the last quarter. Finally, Wedbush Securities Inc. purchased a new position in shares of Aevi Genomic Medicine during the 2nd quarter worth $233,000. Institutional investors and hedge funds own 22.80% of the company’s stock.

Aevi Genomic Medicine Company Profile

Aevi Genomic Medicine, Inc, a clinical stage biopharmaceutical company, researches and develops novel therapies for pediatric onset and life-altering diseases in the United States. The company's lead product candidates include AEVI-001, a glutamatergic neuromodulator, which has completed Phase II/III SAGA trial for the treatment of a genetically-defined subset of adolescent attention deficit hyperactivity disorder patients who have genetic mutations that disrupt the mGluR network resulting in glutamate imbalance; and AEVI-002, an anti-LIGHT monoclonal antibody that is in Phase Ib clinical trial for use in severe pediatric onset Crohn's disease.

Featured Story: Using the New Google Finance Tool

Get a free copy of the Zacks research report on Aevi Genomic Medicine (GNMX)

For more information about research offerings from Zacks Investment Research, visit

Earnings History and Estimates for Aevi Genomic Medicine (NASDAQ:GNMX)

Receive News & Ratings for Aevi Genomic Medicine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aevi Genomic Medicine and related companies with's FREE daily email newsletter.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit